2024年12月1日-6日，全球医药市场共签署了24项资产授权和合作协议。中国市场共达成4项，包括1项出海交易、1项引进交易和2项国内交易。
本周中国市场唯一的出海交易是映恩生物与GSK就新型ADC肿瘤资产DB-1314达成独家授权合作，首付款3000万美元，总价值10.05亿美元。本周最值得关注的引进交易是博锐生物与优时比就已获批资产bimekizumab达成中国市场的商业推广合作。本周两项国内交易分别由新元素与康哲药业、加立生科与远大生命科学达成。
国际市场上，共签署了20项资产授权和合作协议。最大一笔交易是Novartis与PTC就临床2期资产PTC518达成的全球许可协议，首付款10亿美元，总价值29亿美元，成为今年以来全球首付款最大的一笔资产交易。
Between December 1 and 6, a total of 24 licensing and cooperation deals were signed globally. In China biotech sector, there were 4 deals done, including 1 out-licensing deal, 1 in-licensing deal, and 2 domestic deals.
The only out-licensing transactions was between DualityBio and GSK on oncology asset DB-1314 worth $1.005 billion, with an upfront payment of $30 million. The most notable in-licensing deal was UCB and BioRay Pharmaceuticals signed a commercial promotion agreement for the approved asset bimekizumab in Chinese mainland market. The two domestic transactions were done by Atom Bioscience/China Medical System, and Cali Biosciences/Grand Life Sciences separately.
Globally, 20 licensing and cooperation deals were completed, with the most significant being the agreement between PTC Therapeutics and Novartis for the Phase II asset PTC518. This deal featured a record-breaking upfront payment of $1 billion and a total value of $2.9 billion, making it the largest global deal of the year based on upfront payment.
2b. Global section
3. Top Deals of the year 2024
雅法资本成立于2013年，作为新型投资和投行咨询机构，致力于中国及海外生物医药项目的投融资、资产跨境交易和资产孵化等。旗下雅法基金联合药企进行资产投资和并购，雅法全球医疗专注于医药产品跨境及国内授权交易。基于雅法在全球广泛的人脉与资源网络，在过去十年成功推进了大量的海外项目进入中国市场并协助多个中国产品完成海外授权。雅法拥有经验丰富的全球交易团队，覆盖美国、日本 、欧洲等全球主要医药创新区域。核心合伙人均为华尔街资深投行人士或具有跨国药企经历，为客户交易提供强力支持。雅法总部位于上海，在美国、欧洲、东南亚等地均设有分部。雅法在生物医药跨境授权及并购业务交易数量连续多年排名第一。
About YAFO Capital
Founded in 2013, YAFO Capital is a Shanghai based boutique investment and advisory firm, with professional team in our China, U.S., EU and SEA offices. Partnering with Pharmaceutical companies, YAFO Fund mainly invests in global assets. YAFO Life Sciences is a leading advisory boutique focused on asset transactions. YAFO has built a strong proven track record and closed dozens of in-licensing and out-licensing transactions with global pharma and biotech companies. Over the past five years, YAFO has been ranked as the No. 1 advisor for China cross border licensing transactions. For more information, please visit www.yafocapital.com
Event Name:
